CENTO, VALERIA
 Distribuzione geografica
Continente #
NA - Nord America 2.999
AS - Asia 253
EU - Europa 203
SA - Sud America 2
Totale 3.457
Nazione #
US - Stati Uniti d'America 2.996
KR - Corea 122
SG - Singapore 77
CN - Cina 46
UA - Ucraina 38
IT - Italia 29
DE - Germania 27
IE - Irlanda 25
FR - Francia 17
GB - Regno Unito 17
RU - Federazione Russa 15
FI - Finlandia 9
SE - Svezia 8
BE - Belgio 5
PL - Polonia 4
GR - Grecia 3
VN - Vietnam 3
CA - Canada 2
NL - Olanda 2
AE - Emirati Arabi Uniti 1
AR - Argentina 1
BR - Brasile 1
CH - Svizzera 1
DM - Dominica 1
EE - Estonia 1
IN - India 1
JP - Giappone 1
KG - Kirghizistan 1
NO - Norvegia 1
SA - Arabia Saudita 1
VA - Santa Sede (Città del Vaticano) 1
Totale 3.457
Città #
Woodbridge 901
Wilmington 731
Houston 707
Fairfield 124
Chandler 112
Ann Arbor 73
Singapore 72
Ashburn 39
Seattle 36
Cambridge 34
Dearborn 23
Dublin 23
Jacksonville 19
Medford 18
Rome 15
New York 13
Beijing 9
Menlo Park 9
Santa Clara 9
Lawrence 8
Palo Alto 8
Nanjing 7
Zhengzhou 6
Brussels 5
Shanghai 5
Hefei 4
Kraków 4
Kunming 4
Moscow 4
San Diego 4
London 3
Milan 3
Munich 3
Phoenix 3
Council Bluffs 2
Dong Ket 2
Engelhard 2
Monte Vista 2
Nanchang 2
Norwalk 2
Wuhan 2
Amsterdam 1
Apo 1
Athens 1
Baotou 1
Billings 1
Boardman 1
Burlington 1
Caserta 1
Cassino 1
Cedarhurst 1
Chicago 1
Clearwater 1
Dubai 1
Groningen 1
Guangzhou 1
Hanoi 1
Helsinki 1
Indiana 1
Jinan 1
Kherson 1
Mountain View 1
Ningbo 1
Nürnberg 1
Oslo 1
Ottawa 1
Redwood City 1
Riyadh 1
Roseau 1
Simi Valley 1
Stockholm 1
São Paulo 1
Tallinn 1
Tokyo 1
Toronto 1
Verona 1
Totale 3.087
Nome #
HCV-RNA quantification in liver bioptic samples and extrahepatic compartments, using the abbott RealTime HCV assay 446
Hepatitis C virus RNA levels at week-2 of telaprevir/boceprevir administration are predictive of virological outcome 423
Optimal efficacy of interferon-free HCV retreatment after protease inhibitors failure in real life. 392
Exploring resistance pathways for first-generation NS3/4A protease inhibitors boceprevir and telaprevir using Bayesian network learning 390
Improvement of ALT decay kinetics by all-oral HCV treatment: Role of NS5A inhibitors and differences with IFN-based regimens 366
Optimal cure rate by personalized HCV regimens in real-life: a proof-of-concept study 366
Hepatitis C virus genetic variability and the presence of NS5B resistance-associated mutations as natural polymorphisms in selected genotypes could affect the response to NS5B inhibitors 362
Consequences of inaccurate hepatitis C virus genotyping on the costs of prescription of direct antiviral agents in an Italian district 362
Implications of hepatitis C virus subtype 1a migration patterns for virus genetic sequencing policies in Italy 359
Detecting hepatitis B viral amino acid sequence mutations in occult hepatitis B infections via bayesian partition model 19
Temporal trend of drug-resistance and APOBEC editing in PBMC genotypic resistance tests from HIV-1 infected virologically suppressed individuals 17
Totale 3.502
Categoria #
all - tutte 6.780
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 6.780


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020619 0 0 0 0 84 110 103 74 75 80 46 47
2020/2021448 53 52 52 57 33 49 48 49 12 16 17 10
2021/202297 4 4 0 4 0 12 5 8 11 14 6 29
2022/2023204 30 20 28 28 15 32 9 12 26 0 3 1
2023/202452 7 2 6 0 2 13 0 0 13 0 0 9
2024/2025121 10 62 26 12 11 0 0 0 0 0 0 0
Totale 3.502